Podcast: The Not Crazy Episode
In the first episode of Not Crazy or the final episode of A Bipolar, A Schizophrenic and a Podcast, Gabe and Michelle reminisce on past episodes, and Michelle tells us what her plans are for the future. Later, Michelle gives some words of wisdom to Gabe’s new co-host, Jackie Zimmerman. We get to know Jackie and discuss how Gabe and Jackie will be taking over BSP, but with a slightly new direction and a new name! Listen Now to get all the details. SUBSCRIBE &REVIEW About The Hosts Gabe Howard is an award-winning writer and speaker who lives with bipolar disorder. He is the author of the popular book, Mental Illness is an Asshole and other Observations, available from Amazon; signed copies are also available directly from Gabe Howard. To learn more, please visit his website, gabehoward.com. Jackie Zimmerman has been in the patient advocacy game for over a decade and has established herself as an authority on chronic illness, patient-centric healthcare and patient community building. You can find her online at JackieZimmerman.co, Twitter, Facebook and LinkedIn. Computer Generated Transcript for ‘Not Crazy Podcast’ Episode Editor’s Note: Please be mindful that this transcript has been computer generated and therefore may contain inaccuracies and grammar errors. Thank you. Announcer: For reasons that utterly escape everyone involved, you’re listening to A Bipolar, a Schizophrenic, and a Podcast. Here ...
There is good news and bad news when it comes to our understanding of inflammation in the pathogenesis and treatment of major depressive disorder (MDD). The bad news is that, like the dexamethasone suppression test or the efficacy of antidepressants before it, inflammation is oversold as an answer to the mystery of depression and its treatment. The good news is that an unusually replicable set of findings (for psychiatry) increasingly paints a consistent picture of the ways in which inflammation is of value in understanding MDD.
Challenges to the diagnosis and treatment of patients with psychiatric disorders have long been acknowledged in the field. In recent years, efforts have been made to identify genomic biomarkers for psychiatric disorders. A link between immune function and major depressive disorder (MDD) has been suggested for decades (1), but the identification of differentially expressed genes (DEGs) that underlie immune function as biomarkers for MDD has been more recent. Hundreds of DEGs have been reported for transcriptome-wide association studies (TWASs) of MDD.
Our brains are built to consider and reflect on the unknown. These adaptive features protect us from potential threats in dynamic and complex environments, but they can also lead us to perseverate on perceived threats and fear an unknown future. Ranging across a spectrum from adaptive to maladaptive, anxious and fearful behavior exists in many animal species. In an effort to develop new therapeutics and understand the etiology of anxiety-related conditions, such as anxiety disorders, obsessive-compulsive disorder, panic disorder, and posttraumatic stress disorder, research using laboratory animal models has focused on the ...
to: “Major Depressive Disorder Is Associated With Differential Expression of Innate Immune and Neutrophil-Related Gene Networks in Peripheral Blood: A Quantitative Review of Whole-Genome Transcriptional Data From Case-Control Studies,” by Wittenberg et al. (Biol Psychiatry 2020; 88:625–637); http s://doi.org/10.1016/j.biopsych.2020.05.006.
Decline in global cognitive z - score faster for individuals with ≤ 4 hours, ≥ 10 hours of sleep nightly
Abstract Pulmonary comorbidities and ASA physical status class III and IV can significantly increase the rate of major complications after ISC placement. Patients with an underlying pulmonary comorbidity or lung disease (chronic obstructive pulmonary disease, asthma, or obstructive sleep apnea) have a 2.2-fold increased risk of having any complication and a 2.4-fold increased risk of having a major pulmonary complication compared to those without pulmonary comorbidities. Patients with pulmonary comorbidities may benefit from alternative pain management strategies to avoid complications in the early postoperative p...
Sep 30, 2020. . Sponsored by Center on Rural Addiction, University of Vermont
Publication date: Available online 20 September 2020Source: Journal of Theoretical BiologyAuthor(s): Courtney Cochrane, Melissa A. St. Hilaire, Demba Ba
CONCLUSIONS: This study provides further knowledge about patients at risk for co-morbid substance abuse and poor treatment outcomes. Clinicians may consider targeting patients with schizophrenia and other psychoses, young males and those who are socially deprived in efforts to prevent emerging substance abuse and improve outcomes. PMID: 32945698 [PubMed - as supplied by publisher]
More News: Accidents | Anxiety | Appendicitis | Avocados | Bipolar | Children | Computers | Databases & Libraries | Depression | Girls | Health Management | Inflammatory Bowel Disease | Learning | Mania | Men | Multiple Sclerosis | National Institute for Health and Clinical Excelle | Podcasts | Psychology | Pumpkins | Schizophrenia | Sleep Disorders | Sleep Medicine | Sports Medicine | Suicide | Ulcerative Colitis | Universities & Medical Training | Websites